期刊
FRONTIERS IN AGING NEUROSCIENCE
卷 6, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2014.00342
关键词
gamma-Secretase; Alzheimer'sdisease; presenilin; beta-amyloid; Notch; APP; Hif-1 alpha
资金
- NIH [R01AG026660, R01NS076117]
- Alzheimer Association [IIRG-12-242147]
- Met-Life Foundation
- JPB Foundation
- training grant NIH [T32 CA062948]
- Commonwealth Foundation for Cancer Research
- Experimental Therapeutics Center of MSKCC
- William Randolph Hearst Fund in Experimental Therapeutics
gamma-Secretase is a four subunit, 19-pass transmembrane enzyme that cleaves amyloid precursor protein (APP), catalyzing the formation of amyloid beta (A beta) peptides that form amyloid plaques, which contribute to Alzheimer's disease (AD) pathogenesis. gamma-Secretase also cleaves Notch, among many other type I transmembrane substrates. Despite its seemingly promiscuous enzymatic capacity, gamma-secretase activity is tightly regulated. This regulation is a function of many cellular entities, including but not limited to the essential gamma-secretase subunits, nonessential (modulatory) subunits, and gamma-secretase substrates. Regulation is also accomplished by an array of cellular events, such as presenilin (active subunit of gamma-secretase) endoproteolysis and hypoxia. In this review we discuss how gamma-secretase is regulated with the hope that an advanced understanding of these mechanisms will aid in the development of effective therapeutics for gamma-secretase-associated diseases like AD and Notch- addicted cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据